These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
478 related articles for article (PubMed ID: 21410628)
1. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Gomis R; Espadero RM; Jones R; Woerle HJ; Dugi KA Diabetes Obes Metab; 2011 Jul; 13(7):653-61. PubMed ID: 21410628 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Taskinen MR; Rosenstock J; Tamminen I; Kubiak R; Patel S; Dugi KA; Woerle HJ Diabetes Obes Metab; 2011 Jan; 13(1):65-74. PubMed ID: 21114605 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Owens DR; Swallow R; Dugi KA; Woerle HJ Diabet Med; 2011 Nov; 28(11):1352-61. PubMed ID: 21781152 [TBL] [Abstract][Full Text] [Related]
4. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study. Bajaj M; Gilman R; Patel S; Kempthorne-Rawson J; Lewis-D'Agostino D; Woerle HJ Diabet Med; 2014 Dec; 31(12):1505-14. PubMed ID: 24824197 [TBL] [Abstract][Full Text] [Related]
5. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study. Yki-Järvinen H; Rosenstock J; Durán-Garcia S; Pinnetti S; Bhattacharya S; Thiemann S; Patel S; Woerle HJ Diabetes Care; 2013 Dec; 36(12):3875-81. PubMed ID: 24062327 [TBL] [Abstract][Full Text] [Related]
6. The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Singh-Franco D; McLaughlin-Middlekauff J; Elrod S; Harrington C Diabetes Obes Metab; 2012 Aug; 14(8):694-708. PubMed ID: 22340363 [TBL] [Abstract][Full Text] [Related]
7. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Haak T; Meinicke T; Jones R; Weber S; von Eynatten M; Woerle HJ Diabetes Obes Metab; 2012 Jun; 14(6):565-74. PubMed ID: 22356132 [TBL] [Abstract][Full Text] [Related]
8. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Del Prato S; Barnett AH; Huisman H; Neubacher D; Woerle HJ; Dugi KA Diabetes Obes Metab; 2011 Mar; 13(3):258-67. PubMed ID: 21205122 [TBL] [Abstract][Full Text] [Related]
9. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Wainstein J; Katz L; Engel SS; Xu L; Golm GT; Hussain S; O'Neill EA; Kaufman KD; Goldstein BJ Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736 [TBL] [Abstract][Full Text] [Related]
10. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Forst T; Uhlig-Laske B; Ring A; Graefe-Mody U; Friedrich C; Herbach K; Woerle HJ; Dugi KA Diabet Med; 2010 Dec; 27(12):1409-19. PubMed ID: 21059094 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial. Lewin AJ; Arvay L; Liu D; Patel S; von Eynatten M; Woerle HJ Clin Ther; 2012 Sep; 34(9):1909-19.e15. PubMed ID: 22939034 [TBL] [Abstract][Full Text] [Related]
12. Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial. Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M Diabetes Obes Metab; 2015 Feb; 17(2):136-44. PubMed ID: 25298165 [TBL] [Abstract][Full Text] [Related]
13. Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study. Haak T; Meinicke T; Jones R; Weber S; von Eynatten M; Woerle HJ Int J Clin Pract; 2013 Dec; 67(12):1283-93. PubMed ID: 24118640 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Ross SA; Rafeiro E; Meinicke T; Toorawa R; Weber-Born S; Woerle HJ Curr Med Res Opin; 2012 Sep; 28(9):1465-74. PubMed ID: 22816729 [TBL] [Abstract][Full Text] [Related]
15. Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes. Inagaki N; Watada H; Murai M; Kagimura T; Gong Y; Patel S; Woerle HJ Diabetes Obes Metab; 2013 Sep; 15(9):833-43. PubMed ID: 23565760 [TBL] [Abstract][Full Text] [Related]
16. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension. Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280 [TBL] [Abstract][Full Text] [Related]
17. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Barnett AH; Huisman H; Jones R; von Eynatten M; Patel S; Woerle HJ Lancet; 2013 Oct; 382(9902):1413-23. PubMed ID: 23948125 [TBL] [Abstract][Full Text] [Related]
18. Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial. Heo JH; Han KA; Hong JH; Seo HA; Hong EG; Yu JM; Jung HS; Cha BS Diabetes Metab J; 2024 Sep; 48(5):937-948. PubMed ID: 38310875 [TBL] [Abstract][Full Text] [Related]
19. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. DeFronzo RA; Lewin A; Patel S; Liu D; Kaste R; Woerle HJ; Broedl UC Diabetes Care; 2015 Mar; 38(3):384-93. PubMed ID: 25583754 [TBL] [Abstract][Full Text] [Related]
20. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Forst T; Uhlig-Laske B; Ring A; Ritzhaupt A; Graefe-Mody U; Dugi KA Diabetes Obes Metab; 2011 Jun; 13(6):542-50. PubMed ID: 21352464 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]